Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Infection and Immunity

• Publication date

  2011-12-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/IAI.06174-11PMID 22202122PMCID PMC3294653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the bile salt binding site on ipad from Shigella flexneri and the influence of ligand binding on IpaD structure

  2012cited by this paper
• Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant

  2011influential reference
• Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

  2011cited by this paper
• Conformational changes in IpaD from Shigella flexneri upon binding bile salts provide insight into the second step of type III secretion.

  2011cited by this paper
• Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

  2011cited by this paper
• Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

  2011cited by this paper
• Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010.

  2011cited by this paper
• Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.

  2010cited by this paper
• Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine.

  2010cited by this paper
• Emergence of a Novel Shigella flexneri Serotype 4s Strain That Evolved from a Serotype X Variant in China

  2010cited by this paper
• Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

  2010cited by this paper
• Antimicrobial Resistance Trends of Shigella Serotypes in New York City, 2006–2009

  2010cited by this paper
• Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas

  2010cited by this paper
• Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

  2010cited by this paper
• Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection

  2009cited by this paper
• Emergence of a New Multidrug-Resistant Serotype X Variant in an Epidemic Clone of Shigella flexneri

  2009cited by this paper
• Mucosally Delivered Salmonella Typhi Expressing the Yersinia pestis F1 Antigen Elicits Mucosal and Systemic Immunity Early in Life and Primes the Neonatal Immune System for a Vigorous Anamnestic Response to Parenteral F1 Boost1

  2009cited by this paper
• Liposomes Recruit IpaC to the Shigella flexneri Type III Secretion Apparatus Needle as a Final Step in Secretion Induction

  2009cited by this paper
• Magnitude of drug resistant Shigellosis: a report from Bangalore.

  2009cited by this paper
• Safety and Immunogenicity of CVD 1208S, a Live, Oral ΔguaBA Δsen Δset Shigella flexneri 2a Vaccine Grown on Animal-Free Media

  2007cited by this paper
• Bile Salts Stimulate Recruitment of IpaB to the Shigella flexneri Surface, Where It Colocalizes with IpaD at the Tip of the Type III Secretion Needle

  2007cited by this paper
• Preparation and characterization of translocator/chaperone complexes and their component proteins from Shigella flexneri.

  2007influential reference
• Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

  2007cited by this paper
• IpaD Localizes to the Tip of the Type III Secretion System Needle of Shigella flexneri

  2006cited by this paper
• Isolation and characterization

  2006cited by this paper
• Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

  2006cited by this paper
• Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

  2006cited by this paper
• Spectroscopic and calorimetric analyses of invasion plasmid antigen D (IpaD) from Shigella flexneri reveal the presence of two structural domains.

  2006cited by this paper
• Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.

  2005cited by this paper
• Roles for T and NK Cells in the Innate Immune Response to Shigella flexneri1

  2005cited by this paper
• Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

  2004cited by this paper
• Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers

  2004cited by this paper
• Adult Volunteers

  2003cited by this paper
• Structure-Function Analysis of Invasion Plasmid Antigen C (IpaC) from Shigella flexneri *

  2003cited by this paper
• Delayed and Reduced Adaptive Humoral Immune Responses in Children with Shigellosis Compared with in Adults

  2002cited by this paper
• Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults

  2001cited by this paper
• Safety and Immunogenicity of ImprovedShigella O-Specific Polysaccharide-Protein Conjugate Vaccines in Adults in Israel

  2001cited by this paper
• Isolation and Characterization of a Shigella flexneri Invasin Complex Subunit Vaccine

  2000cited by this paper
• Production of IFN-γ and IL-10 to Shigella Invasins by Mononuclear Cells from Volunteers Orally Inoculated with a Shiga Toxin-Deleted Shigella dysenteriae Type 1 Strain1

  2000cited by this paper
• Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.

  1999cited by this paper
• The Tripartite Type III Secreton of Shigella flexneri Inserts Ipab and Ipac into Host Membranes

  1999cited by this paper
• An Essential Role for Gamma Interferon in Innate Resistance to Shigella flexneri Infection

  1998cited by this paper
• Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers

  1996cited by this paper
• Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection

  1995cited by this paper
• Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.

  1995cited by this paper
• Extracellular association and cytoplasmic partitioning of the IpaB and IpaC invasins of S. flexneri.

  1994cited by this paper
• Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.

  1993cited by this paper
• Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients

  1993cited by this paper
• Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.

  1992cited by this paper
• Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins.

  1992cited by this paper
• Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis

  1991cited by this paper
• Inoculum size in shigellosis and implications for expected mode of transmission.

  1989cited by this paper
• Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

  1988cited by this paper
• Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1

  1988cited by this paper
• Serum factors capable of opsonizing Shigella for phagocytosis by polymorphonuclear neutrophils.

  1975cited by this paper
• Structural Biology and Crystallization Communications Expression, Limited Proteolysis and Preliminary Crystallographic Analysis of Ipad, a Component of the Shigella Flexneri Type Iii Secretion System

  year unknowncited by this paper

• Shigella sonnei and Shigella flexneri: Epidemiology supporting development of cross-protective vaccines

  2026cites this paper
• Immunoinformatics-based design of a next generation multi-epitope vaccine candidate against Shigella boydii using a hierarchical subtractive proteomics approach

  2025cites this paper
• Effects of improved water, sanitation, handwashing and nutrition on early childhood IgG immune repertoire development against Shigella and enteroinvasive Escherichia coli (EIEC)

  2025cites this paper
• Discovery of protease inhibitors from bacteria as novel adjuvants for oral vaccine formulations

  2025cites this paper
• Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibit Shigella flexneri invasion

  2025cites this paper
• Characterization of Shigella virulence factor intracellular spread A (IcsA, or VirG) functional epitopes against S. flexneri 2a and S. sonnei invasion and adherence

  2025cites this paper
• An in-silico-designed multiepitope vaccine candidate can efficiently protect mice against pathogenic species of Shigella.

  2025cites this paper
• The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal Shigella challenge after prior exposure

  2025cites this paper
• Shigella Mutant with Truncated O-Antigen as an Enteric Multi-Pathogen Vaccine Platform

  2025cites this paper
• Spatial visualization provides insight into immune modulation by an L-DBF vaccine formulation against Shigella

  2025cites this paper
• Efficient production of a novel recombinant fusion protein of EIEC effector IpaD and EGFP: Biophysical characterization and functional studies.

  2025cites this paper
• A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system

  2025cites this paper
• Conserved antigens for enteric vaccines

  2025cites this paper
• Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality of Shigella-specific antibodies

  2024cites this paper
• A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine

  2024influential citation
• Plant‐Made Vaccines Targeting Enteric Pathogens—Safe Alternatives for Vaccination in Developing Countries

  2024cites this paper
• Impact of an intranasal L-DBF vaccine on the gut microbiota in young and elderly mice

  2024cites this paper
• Targeted Antimicrobial Therapies: A Solution to Overcoming Antimicrobial Resistance in Humans

  2024cites this paper
• Limited O-specific polysaccharide (OSP)-specific functional antibody responses in young children with Shigella infection in Bangladesh

  2024cites this paper
• Mapping the functional B-cell epitopes of Shigella invasion plasmid antigen D (IpaD)

  2024cites this paper
• Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

  2024cites this paper
• Shigella Vaccines: The Continuing Unmet Challenge

  2024cites this paper
• Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate

  2024cites this paper
• A tetravalent Shigella Outer Membrane Vesicles based candidate vaccine offered cross-protection against all the serogroups of Shigella in adult mice.

  2023cites this paper
• Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries

  2023cites this paper
• A broadly immunogenic polyvalent Shigella multiepitope fusion antigen protein protects against Shigella sonnei and Shigella flexneri lethal pulmonary challenges in mice

  2023influential citation
• The L-DBF vaccine cross protects mice against different Shigella serotypes after prior exposure to the pathogen

  2023cites this paper
• Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.

  2023cites this paper
• GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers.

  2023cites this paper
• Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccines

  2023cites this paper
• Immunogenicity and protective efficacy of nanoparticle formulations of L-SseB against Salmonella infection

  2023cites this paper
• Functional assays to evaluate antibody-mediated responses against Shigella: a review

  2023cites this paper
• A Novel Shigella O-Polysaccharide–IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes

  2023influential citation
• Investigate the immunogenic and protective effect of trivalent chimeric protein containing IpaD-StxB-TolC antigens as a vaccine candidate against S. dysenteri and S. flexneri.

  2023cites this paper
• A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection

  2023cites this paper
• Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology

  2023cites this paper
• Label free flexible electrochemical DNA biosensor for selective detection of Shigella flexneri in real food samples.

  2022cites this paper
• Systems approach to define humoral correlates of immunity to Shigella

  2022cites this paper
• Exploring the use of Congo red agar in improving the serotyping of non-serotypeable Shigella with In-silico evidence.

  2022cites this paper
• Shigella-Controlled Human Infection Models: Current and Future Perspectives

  2022cites this paper
• Stable Recombinant Invasion Plasmid Antigen C (IpaC)-Based Single Dose Nanovaccine for Shigellosis.

  2022cites this paper
• From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and Evolution

  2022cites this paper
• A Comprehensive Computational Investigation into the Conserved Virulent Proteins of Shigella species Unveils Potential Small-Interfering RNA Candidates as a New Therapeutic Strategy against Shigellosis

  2022cites this paper
• Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics

  2022cites this paper
• Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs

  2022cites this paper
• Cloning, improved expression and purification of invasion plasmid antigen D (IpaD): an effector protein of enteroinvasive Escherichia coli (EIEC)

  2022cites this paper
• An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections

  2021cites this paper
• The role of vaccines in combatting antimicrobial resistance

  2021cites this paper
• The Shigella Type III Secretion System: An Overview from Top to Bottom

  2021cites this paper
• Design and Recombinant Expression of a multiepitope Vaccine Candidate Against Pathogenic Species of Shigella

  2021cites this paper
• Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system

  2021cites this paper
• L-DBF Elicits Cross Protection Against Different Serotypes of Shigella spp

  2021cites this paper
• Development of a Self-Adjuvanting, Cross-Protective, Stable Intranasal Recombinant Vaccine for Shigellosis.

  2021cites this paper
• An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.

  2021cites this paper
• Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa

  2021cites this paper
• Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease

  2021cites this paper
• Informing shigellosis prevention and control through pathogen genomics

  2021cites this paper
• A comprehensive computational investigation into the conserved virulent proteins of Shigella sp unveils potential siRNA candidates as a new therapeutic strategy against shigellosis

  2021cites this paper
• Oral Shigella Vaccines

  2020cites this paper
• Designation of chitosan nano-vaccine based on MxiH antigen of Shigella flexneri with increased immunization capacity.

  2020cites this paper
• Development of Silica-Immobilized Vaccines for Improving Thermo-Tolerance and Shelf-Life

  2020cites this paper
• SipD and IpaD induce a cross-protection against Shigella and Salmonella infections

  2020cites this paper
• Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model.

  2020cites this paper
• Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.

  2020cites this paper
• Preformulation Characterization and the Effect of Ionic Excipients on the Stability of a Novel DB Fusion Protein

  2020cites this paper
• Intranasal vaccination with a Chimeric Chlamydial Antigen BD584 confers protection against Chlamydia trachomatis genital tract infection

  2020cites this paper
• Shigella sonnei: virulence and antibiotic resistance

  2020cites this paper
• Intranasal Immunization of Mice with Multiepitope Chimeric Vaccine Candidate Based on Conserved Autotransporters SigA, Pic and Sap, Confers Protection against Shigella flexneri

  2020cites this paper
• Protein Stabilization and Delivery: A Case Study of Invasion Plasmid Antigen D Adsorbed on Porous Silica.

  2020cites this paper
• Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa

  2020cites this paper
• Protein Export and Secretion Among Bacterial Pathogens

  2020cites this paper
• A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice

  2019cites this paper
• Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis

  2019cites this paper
• In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin

  2019cites this paper
• ارزیابی میزان ایمنی زایی آنتی ژن IpaD متصل شده به لیگاندهای Co1 و STxB بهصورت نازال بر علیه باکتری E. coli سویه O157:H7 در موش سوری

  2019cites this paper
• Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model

  2018cites this paper
• A Novel Shigella Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge

  2018cites this paper
• Impact of Detergent on the Biophysical Properties and Immune Response of the IpaDB Fusion Protein , a Candidate Subunit Vaccine against Shigella spp .

  2018cites this paper
• Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex

  2018influential citation
• T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans

  2018cites this paper
• The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT

  2018cites this paper
• Characterization and Protective Efficacy of Type III Secretion Proteins as a Broadly Protective Subunit Vaccine against Salmonella enterica Serotypes

  2018cites this paper
• Development & Expression Of A Novel Synthetic Flagellin Fusion Protein Containing A Shigella Toxoid Subunit As A Potential Vaccine Against Shigellosis & Stec

  2017cites this paper
• An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype

  2017cites this paper
• Transferon™, a peptide mixture with immunomodulatory properties is not immunogenic when administered with various adjuvants

  2017cites this paper
• Effective protection of mice against Shigella flexneri with a new self‐adjuvant multicomponent vaccine

  2017cites this paper
• Mouse Immunization with Purified Needle Proteins from Type III Secretion Systems and the Characterization of the Immune Response to These Proteins.

  2017cites this paper
• Exploration of Specific DNA-Barcodes in Shigella dysenteriae Using In-silico Analysis

  2017cites this paper
• Immunogenicity of Chitosan Nanogel Containing IpaC Recombinant Protein from Shigella in Guinea Pig

  2017cites this paper
• Type III Secretion in the Melioidosis Pathogen Burkholderia pseudomallei

  2017cites this paper
• Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection

  2017cites this paper
• In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate

  2017cites this paper
• Immunization with chlamydial type III secretion antigens reduces vaginal shedding and prevents fallopian tube pathology following live C. muridarum challenge.

  2016cites this paper
• Detergent Isolation Stabilizes and Activates the Shigella Type III Secretion System Translocator Protein IpaC.

  2016cites this paper
• The Many Faces of IpaB

  2016cites this paper
• Subversion of host cellular processes by the melioidosis pathogen, Burkholderia pseudomallei

  2016cites this paper
• The genomic signatures of Shigella evolution, adaptation and geographical spread

  2016cites this paper
• Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study

  2016cites this paper
• Development of recombinant vaccine candidate molecule against Shigella infection.

  2016cites this paper
• Status of vaccine research and development for Shigella.

  2016cites this paper